Trial reportThe Prostate2013
A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men.
Trial report in The Prostate, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer.Nature communications · 2015Pooled it
- G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- HOXB13, a high-risk prostate cancer gene, also confers risk for breast cancer: novel variants of clinical significance, especially in hormone-positive patients.Journal of human genetics · 2026Article
- From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis.Translational oncology · 2026Review
- HOXB13 in cancer development: molecular mechanisms and clinical implications.Frontiers of medicine · 2025Review
- Delineating the roles of HOXB13 X285K variant in prostate cancer.Serican journal of medicine · 2025Article
- Article
- Clinical and Functional Analyses of an African-ancestry Gain-of-function HOXB13 Variant Implicated in Aggressive Prostate Cancer.European urology oncology · 2024Article
- Prostate cancer genetic background. The introduction of genetic testing in the determination of high-risk prostate cancer cases and selection of targeted chemotherapy in advanced prostate cancer patients.Central European journal of urology · 2024Review
- Clinicopathological Characteristics and Mutational Landscape ofCurrent issues in molecular biology · 2023Article
- Exome sequencing of affected duos and trios uncovers PRUNE2 as a novel prostate cancer predisposition gene.British journal of cancer · 2023Article
- Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.British journal of cancer · 2022Article
- A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.European urology · 2022Article
- Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview.The world journal of men's health · 2022Review
- Rereading the genetic origin of cancer: the puzzle of all eras.Future science OA · 2022Article
- Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.JNCI cancer spectrum · 2022Article
- Health inequity drives disease biology to create disparities in prostate cancer outcomes.The Journal of clinical investigation · 2022Review
- Germline Mutations in Patients With Early-Onset Prostate Cancer.Frontiers in oncology · 2022Article
- The prevalence and clinical implication of rare germline deleterious alterations in Chinese patients with prostate cancer: A real-world multicenter study.Clinical and translational medicine · 2021Article
- Epidemiology and genomics of prostate cancer in Asian men.Nature reviews. Urology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors at 20 institutions in 2 countries.
Funding
Abstract
backgroundA rare mutation G84E in HOXB13 was recently identified to be associated with prostate cancer (PCa) in Caucasians. The goal of this study is to test association between HOXB13 genetic variants and PCa risk in Chinese men.
methodsAll study subjects were part of the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa). In the first stage, we screened for mutations by sequencing the HOXB13 coding region in 96 unrelated PCa patients. In stage 2, G84E and novel mutations found in stage 1 were genotyped in 671 PCa patients and 1,536 controls. In stage 3, mutation status in 751 additional PCa patients was imputed via haplotype.
resultsThe G84E mutation was not detected in this study. However, a novel mutation, G135E, was identified among 96 patients in stage 1. It was also observed twice in 575 additional PCa patients but not in 1,536 control subjects of stage 2. The frequency of G135E was significantly different between cases and controls, with a P-value of 0.027, based on Fisher's exact test. Haplotype estimation showed that G135E mutation carriers shared a unique haplotype that was not observed in other subjects. In stage 3, two more PCa patients were predicted to carry the G135E mutation.
conclusionsWe identified a novel rare mutation in the HOXB13 gene, G135E, which appears to be a founder mutation. This mutation is associated with increased PCa risk in Chinese men. Consistent with a previous report, our findings provide further evidence that rare mutations in HOXB13 contribute to PCa risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.